General
Preferred name
BROTIZOLAM
Synonyms
Sintonal ()
WE 941 ()
Nimbisan ()
WE-941 ()
WE-941-BS ()
Lendorm ()
Mederantil ()
Lendormin ()
P&D ID
PD009405
CAS
57801-81-7
Tags
available
drug
First approval
1983
1984
Drug Status
approved
withdrawn
Max Phase
4.0
Drug indication
Insomnia
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Brotizolam is indicated for 2-4 weeks in the treatment of severe or debilitating insomnia.
Compound Sets
12
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
NPC Screening Collection
Withdrawn 2.0
External IDs
43
Properties
(calculated by RDKit )
Molecular Weight
391.95
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
3
cLogP
4.4
TPSA
43.07
Fraction CSP3
0.13
Chiral centers
0.0
Largest ring
7.0
QED
0.61
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
ATC
N05CD09
Toxicity type
NULL
Source data